FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Drug

Iclusig (ponatinib) · Bcr-Abl inhibitor

Conditions

LymphoidOther hematologic neoplasm